Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2.

Eng C, Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, Garcia-Alfonso P, Kocsis J, Gracian AC, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Yang Z, Guevara F, Schelman W, Pallai R, Tabernero J

Open source

DOI: 10.1093/oncolo/oyae360
Published: 2025 Mar 10
Container: The oncologist
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyae360,
  title = {Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2.},
  author = {Eng C and Dasari A and Lonardi S and Garcia-Carbonero R and Elez E and Yoshino T and Sobrero A and Yao J and Garcia-Alfonso P and Kocsis J and Gracian AC and Sartore-Bianchi A and Satoh T and Randrian V and Tomasek J and Chong G and Yang Z and Guevara F and Schelman W and Pallai R and Tabernero J},
  year = {2025},
  journal = {The oncologist},
  doi = {10.1093/oncolo/oyae360},
  url = {https://doi.org/10.1093/oncolo/oyae360}
}

RIS

TY  - JOUR
TI  - Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2.
AU  - Eng C
AU  - Dasari A
AU  - Lonardi S
AU  - Garcia-Carbonero R
AU  - Elez E
AU  - Yoshino T
AU  - Sobrero A
AU  - Yao J
AU  - Garcia-Alfonso P
AU  - Kocsis J
AU  - Gracian AC
AU  - Sartore-Bianchi A
AU  - Satoh T
AU  - Randrian V
AU  - Tomasek J
AU  - Chong G
AU  - Yang Z
AU  - Guevara F
AU  - Schelman W
AU  - Pallai R
AU  - Tabernero J
PY  - 2025
JO  - The oncologist
DO  - 10.1093/oncolo/oyae360
UR  - https://doi.org/10.1093/oncolo/oyae360
ER  -

APA

C, E., A, D., S, L., R, G., E, E., T, Y., A, S., J, Y., P, G., J, K., AC, G., A, S., T, S., V, R., J, T., G, C., Z, Y., F, G., W, S., R, P., & J, T. (2025). Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2.. The oncologist. https://doi.org/10.1093/oncolo/oyae360

Source records

pubmed · retrieved 2026-09-26T14:04:16.650Z